STROKE-CARD care to prevent cardiovascular events and improve quality of life after acute ischaemic stroke or TIA: A randomised clinical trial

Peter Willeit, Thomas Toell, Christian Boehme, Stefan Krebs, Lukas Mayer, Clemens Lang, Lisa Seekircher, Lena Tschiderer, Karin Willeit, Gerhard Rumpold, Gudrun Schoenherr, Andrea Griesmacher, Julia Ferrari, Michael Knoflach, Wilfried Lang, Stefan Kiechl, Johann Willeit, STROKE-CARD study group, Peter Willeit, Thomas Toell, Christian Boehme, Stefan Krebs, Lukas Mayer, Clemens Lang, Lisa Seekircher, Lena Tschiderer, Karin Willeit, Gerhard Rumpold, Gudrun Schoenherr, Andrea Griesmacher, Julia Ferrari, Michael Knoflach, Wilfried Lang, Stefan Kiechl, Johann Willeit, STROKE-CARD study group

Abstract

Background: Patients with ischaemic stroke or transient ischaemic attack (TIA) are at high risk of recurrent stroke and other cardiovascular diseases and commonly suffer from reduced quality of life. We aimed to determine whether the disease management programme STROKE-CARD can prevent cardiovascular diseases and improve quality of life in these patients.

Methods: In this pragmatic open-label two-centre randomised controlled trial with blinded outcome assessment, we randomly assigned patients with acute ischaemic stroke or TIA (ABCD2 score ≥3) in a 2:1 ratio to receive STROKE-CARD care or standard care. STROKE-CARD care is a disease management programme by a multidisciplinary stroke team that comprises a standardised 3-month visit and access to a web-based patient portal targeting risk factor management, post-stroke complications, comorbidities and cardiovascular warning signs, rehabilitation demands, and patient education, counselling, and self-empowerment. Co-primary outcomes were analysed on an intention-to-treat basis and were: (i) major cardiovascular disease events defined as nonfatal ischaemic or haemorrhagic stroke, nonfatal myocardial infarction, or vascular death occurring between hospital discharge and 12 months; and (ii) health-related quality of life at 12 months quantified with the EuroQol-5-Dimensions-3-Levels (EQ-5D-3L) overall utility score. This trial is registered with ClinicalTrials.gov, number NCT02156778.

Findings: Of 2149 patients enrolled between January 2014 and December 2017 (mean age 69 years, 41% female, 83% with ischaemic stroke, 17% with TIA), 1438 were assigned to STROKE-CARD care and 711 to standard care. Major cardiovascular disease events occurred in 78 patients in the STROKE-CARD care group (5.4%) and in 59 patients in the standard care group (8.3%) (hazard ratio, 0.63; 95% confidence interval: 0.45-0.88; P=0.007). STROKE-CARD care also led to a better EQ-5D-3L overall utility score at 12 months (P<0.001). Among pre-specified secondary outcomes, STROKE-CARD care improved all individual EQ-5D-3L dimensions and functional outcome on the modified Rankin Scale at 12 months. Post hoc explanatory analyses identified considerable demands for additional rehabilitation and refinement of preventive therapy regimes at the 3-month visit and high proportions of post-stroke complications and warning signs of imminent cardiovascular diseases within the first three months.

Interpretation: The pragmatic and easily implementable STROKE-CARD care programme reduced cardiovascular risk and improved health-related quality of life and functional outcome in patients with acute ischaemic stroke or TIA.

Funding: Tirol Kliniken, Tyrolean Health Insurance Company, Tyrol Health Care Funds, Boehringer Ingelheim, Nstim Services, Sanofi, Bayer Healthcare.

Keywords: Disease management programme; Ischaemic stroke; Quality of life; Randomised controlled trial; Secondary prevention; Transient ischaemic attack.

© 2020 The Author(s).

Figures

Fig. 1
Fig. 1
CONSORT diagram.
Fig. 2
Fig. 2
Effect of STROKE-CARD care on the co-primary outcomes.
Fig. 3
Fig. 3
Effect of STROKE-CARD care on the pre-specified secondary outcomes.
Fig. 4
Fig. 4
Functional outcome at 12 months assessed with the modified Rankin Scale.
Fig. 5
Fig. 5
Effect of STROKE-CARD care on potential side effects of intensified secondary prevention.

References

    1. GBD 2017 Causes of Death Collaborators Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–1788. doi: 10.1016/S0140-6736(18)32203-7.
    1. GBD 2016 Causes of Death Collaborators Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–1210. doi: 10.1016/S0140-6736(17)32152-9.
    1. Amarenco P, Lavallée PC, Monteiro Tavares L. Five-year risk of stroke after TIA or minor ischemic stroke. N Engl J Med. 2018;378:2182–2190. doi: 10.1056/NEJMoa1802712.
    1. Bergström L, Irewall A-L, Söderström L, Ögren J, Laurell K, Mooe T. One-year incidence, time trends, and predictors of recurrent ischemic stroke in sweden from 1998 to 2010: an observational study. Stroke. 2017;48:2046–2051. doi: 10.1161/STROKEAHA.117.016815.
    1. Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke. 1999;30:338–349.
    1. Boulanger M, Béjot Y, Rothwell PM, Touzé E. Long-term risk of myocardial infarction compared to recurrent stroke after transient ischemic attack and ischemic stroke: systematic review and meta-analysis. J Am Heart Assoc. 2018;7 doi: 10.1161/JAHA.117.007267.
    1. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke. 2007;38:1881–1885. doi: 10.1161/STROKEAHA.106.475525.
    1. Chowdhury R, Khan H, Heydon E. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940–2948. doi: 10.1093/eurheartj/eht295.
    1. Bridgwood B, Lager KE, Mistri AK, Khunti K, Wilson AD, Modi P. Interventions for improving modifiable risk factor control in the secondary prevention of stroke. Cochrane Database Syst Rev. 2018;5 doi: 10.1002/14651858.CD009103.pub3.
    1. Toell T, Boehme C, Mayer L. Pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack -study protocol. BMC Neurol. 2018;18:187. doi: 10.1186/s12883-018-1185-2.
    1. Sacco RL, Kasner SE, Broderick JP. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American heart association/american stroke association. Stroke. 2013;44:2064–2089. doi: 10.1161/STR.0b013e318296aeca.
    1. Johnston SC, Rothwell PM, Nguyen-Huynh MN. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet. 2007;369:283–292. doi: 10.1016/S0140-6736(07)60150-0.
    1. Willeit J, Geley T, Schöch J. Thrombolysis and clinical outcome in patients with stroke after implementation of the Tyrol Stroke Pathway: a retrospective observational study. Lancet Neurol. 2015;14:48–56. doi: 10.1016/S1474-4422(14)70286-8.
    1. Mayer L, Ferrari J, Krebs S. ABCD3-I score and the risk of early or 3-month stroke recurrence in tissue- and time-based definitions of TIA and minor stroke. J Neurol. 2018;265:530–534. doi: 10.1007/s00415-017-8720-8.
    1. Thygesen K, Alpert JS, Jaffe AS. Fourth Universal Definition of Myocardial Infarction (2018) J Am Coll Cardiol. 2018;72:2231–2264. doi: 10.1016/j.jacc.2018.08.1038.
    1. Szende A, Janssen B, Cabases J, editors. Self-reported population health: an international perspective based on EQ-5D. Springer; Netherlands. Dordrecht: 2014.
    1. Greiner W, Weijnen T, Nieuwenhuizen M. A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ. 2003;4:222–231. doi: 10.1007/s10198-003-0182-5.
    1. Dmitrienko A, D'Agostino RB. Multiplicity considerations in clinical trials. N Engl J Med. 2018;378:2115–2122. doi: 10.1056/NEJMra1709701.
    1. McNutt L-A, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol. 2003;157:940–943.
    1. Peng B, Ni J, Anderson CS. Implementation of a structured guideline-based program for the secondary prevention of ischemic stroke in China. Stroke. 2014;45:515–519. doi: 10.1161/STROKEAHA.113.001424.
    1. Fukuoka Y, Hosomi N, Hyakuta T. Effects of a Disease Management Program for Preventing Recurrent Ischemic Stroke. Stroke. 2019;50:705–712. doi: 10.1161/STROKEAHA.118.020888.
    1. Ahmadi M, Laumeier I, Ihl T. A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPiRE-TMS): an open-label, randomised controlled trial. Lancet Neurol. 2019 doi: 10.1016/S1474-4422(19)30369-2.
    1. Barker-Collo S, Krishnamurthi R, Witt E. Improving adherence to secondary stroke prevention strategies through motivational interviewing: randomized controlled trial. Stroke. 2015;46:3451–3458. doi: 10.1161/STROKEAHA.115.011003.
    1. Boter H. Multicenter randomized controlled trial of an outreach nursing support program for recently discharged stroke patients. Stroke. 2004;35:2867–2872. doi: 10.1161/01.STR.0000147717.57531.e5.
    1. Fu VWY, Weatherall M, McPherson K. Taking Charge after Stroke: A randomized controlled trial of a person-centered, self-directed rehabilitation intervention. Int J Stroke. 2020 doi: 10.1177/1747493020915144.
    1. Kamel H, Merkler AE, Iadecola C, Gupta A, Navi BB. Tailoring the approach to embolic stroke of undetermined source: a review. JAMA Neurol. 2019 doi: 10.1001/jamaneurol.2019.0591.
    1. Diener H-C. The cause of stroke matters for secondary prevention. Lancet Neurol. 2017;16:256–257. doi: 10.1016/S1474-4422(17)30057-1.
    1. Heuschmann PU, Kircher J, Nowe T. Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. Eur J Cardiovasc Prev Rehabil. 2015;22:1354–1362. doi: 10.1177/2047487314546825.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit